Literature DB >> 20566794

Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver.

Kristina I Ringe1, Daniela B Husarik, Claude B Sirlin, Elmar M Merkle.   

Abstract

OBJECTIVE: The purpose of this article is to review the pharmacokinetic and pharmacodynamic properties of gadoxetate disodium (Gd-EOB-DTPA), to describe a workflow-optimized pulse sequence protocol, and to illustrate the imaging appearance of focal lesions in the noncirrhotic liver.
CONCLUSION: Gd-EOB-DTPA allows a comprehensive evaluation of the liver with the acquisition of both dynamic and hepatocyte phase images. This provides potential additional information, especially for the detection and characterization of small liver lesions. However, protocol optimization is necessary for improved image quality and workflow.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566794     DOI: 10.2214/AJR.10.4392

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  80 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

2.  Gaucher disease in the liver on hepatocyte specific contrast agent enhanced MR imaging.

Authors:  Rama S Ayyala; Lisa A Teot; Jeanette M Perez Rossello
Journal:  Pediatr Radiol       Date:  2017-02-01

3.  Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol.

Authors:  Julian A Luetkens; Patrick A Kupczyk; Jonas Doerner; Rolf Fimmers; Winfried A Willinek; Hans H Schild; Guido M Kukuk
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

4.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

Review 5.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

6.  Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Nobuhiro Fujita; Yuichiro Kubo; Shinichi Aishima; Ken Shirabe; Takashi Yoshiura; Hiroshi Honda
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

Review 7.  Gadolinium Deposition and Liver MRI.

Authors:  Robert M Marks; Ryan M Ash; James T Lee
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 8.  Hepatocyte-specific contrast media: not so simple.

Authors:  Andrew T Trout; Alexander J Towbin; Ethan A Smith; Anita Gupta; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2018-08-04

9.  Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children.

Authors:  Govind B Chavhan; Erika Mann; Binita M Kamath; Paul S Babyn
Journal:  Pediatr Radiol       Date:  2014-04-27

10.  Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma.

Authors:  Hanke J Schalkx; Marijn van Stralen; Kenneth Coenegrachts; Maurice A A J van den Bosch; Charlotte S van Kessel; Richard van Hillegersberg; Karel J van Erpecum; Helena M Verkooijen; Josien P W Pluim; Wouter B Veldhuis; Maarten S van Leeuwen
Journal:  Eur Radiol       Date:  2014-07-05       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.